Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ygyno.2014.10.011 http://scihub22266oqcxt.onion/10.1016/j.ygyno.2014.10.011 C4268303!4268303!25455733     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Gynecol+Oncol 2014 ; 135 (3): 614-21 Nephropedia Template TP {{tp|p=25455733|t=2014. Old drug, new trick: Repurposing metformin for gynecologic cancers?|pdf=|usr=}}{{25455733}} gab.com Text Old drug, new trick: Repurposing metformin for gynecologic cancers JO: Gynecol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=25455733 #FOAvip Objective: There is increasing pre-clinical and clinical evidence that metformin, a commonly used diabetes medication, has a protective effect in cancer. The aim of this review is to discuss metformin's anti-cancer molecular mechanisms of action and to summarize the current literature demonstrating metformin's potential in gynecologic cancer prevention and treatment. Methods: A PubMed search was conducted combining the keywords ?metformin? with ?neoplasm?, ?uterine neoplasms?, ?ovarian neoplasms?, and ?uterine cervical neoplasms?. Studies published in English between 1994 and 2014 were included. Results: Pre-clinical studies in endometrial, ovarian, and cervical cancer suggest that metformin inhibits the growth of cancer cells. The primary molecular mechanism mediating this effect appears to be the activation of AMP-activated protein kinase (AMPK) and the subsequent inhibition of mammalian targets of rapamycin (mTOR). The pre-clinical findings are augmented by clinical studies indicating that metformin use is associated with a reduced risk of cancer and improved survival in diabetic women with ovarian and endometrial cancer. No clinical analyses have evaluated metformin use and cervical cancer. Overall, the data showing a favorable effect of metformin is strongest for endometrial and ovarian cancer and prospective clinical testing is ongoing in these two malignancies. Conclusions: Numerous clinical studies have reported an association between metformin use by diabetic patients and improved outcomes in gynecologic cancers. In addition, pre-clinical reports have identified plausible biological mechanisms to explain the molecular mechanism of action of metformin in cancer. However, the most important question remains unanswered: Will metformin be effective against cancer in patients without diabetes? Until this question is answered with prospective clinical testing, the role of metformin in the treatment or prevention of gynecologic malignancies remains theoretical and the clinical use of metformin as a cancer therapeutic is experimental. Twit Text FOAVip Old drug, new trick: Repurposing metformin for gynecologic cancers ????Gynecol Oncol http://www.kidney.de/pget.php?&tw=1&pmid=25455733 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25455733 #FOAvip English Wikipedia <ref>{{Cite pmid|25455733}}</ref> Old drug, new trick: Repurposing metformin for gynecologic cancers? #MMPMID25455733 Febbraro T; Lengyel E; Romero IL Gynecol Oncol 2014[Dec]; 135 (3): 614-21 PMID25455733show ga Objective: There is increasing pre-clinical and clinical evidence that metformin, a commonly used diabetes medication, has a protective effect in cancer. The aim of this review is to discuss metformin's anti-cancer molecular mechanisms of action and to summarize the current literature demonstrating metformin's potential in gynecologic cancer prevention and treatment. Methods: A PubMed search was conducted combining the keywords ?metformin? with ?neoplasm?, ?uterine neoplasms?, ?ovarian neoplasms?, and ?uterine cervical neoplasms?. Studies published in English between 1994 and 2014 were included. Results: Pre-clinical studies in endometrial, ovarian, and cervical cancer suggest that metformin inhibits the growth of cancer cells. The primary molecular mechanism mediating this effect appears to be the activation of AMP-activated protein kinase (AMPK) and the subsequent inhibition of mammalian targets of rapamycin (mTOR). The pre-clinical findings are augmented by clinical studies indicating that metformin use is associated with a reduced risk of cancer and improved survival in diabetic women with ovarian and endometrial cancer. No clinical analyses have evaluated metformin use and cervical cancer. Overall, the data showing a favorable effect of metformin is strongest for endometrial and ovarian cancer and prospective clinical testing is ongoing in these two malignancies. Conclusions: Numerous clinical studies have reported an association between metformin use by diabetic patients and improved outcomes in gynecologic cancers. In addition, pre-clinical reports have identified plausible biological mechanisms to explain the molecular mechanism of action of metformin in cancer. However, the most important question remains unanswered: Will metformin be effective against cancer in patients without diabetes? Until this question is answered with prospective clinical testing, the role of metformin in the treatment or prevention of gynecologic malignancies remains theoretical and the clinical use of metformin as a cancer therapeutic is experimental. äOld drug, new trick: Repurposing metformin for gynecologic cancers?(epmc).pdf DeepDyve Pubget Overpricing